Our policy simulation modeling projected that, compared with continuous long-term full-dose GLP-1/IM use, participation in a less expensive alternative weight-maintenance program following a weight-loss plateau would significantly reduce AOM-related spending and produce minimal reductions in lifetime QALYs over a wide range of relatively lower price and effectiveness indices. This evidence concerns the gene GCG and infectious otitis media.